Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001377779 | SCV001575202 | likely pathogenic | Hereditary antithrombin deficiency | 2020-06-29 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Pro353 amino acid residue in SERPINC1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 25522812, 21264449, 24162787 25522812). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has been observed in individual(s) with antithrombin deficiency (PMID: 14754620, 29153735). This variant is also known as Pro321Ser in the literature. This variant is not present in population databases (ExAC no frequency). This sequence change replaces proline with serine at codon 353 of the SERPINC1 protein (p.Pro353Ser). The proline residue is highly conserved and there is a moderate physicochemical difference between proline and serine. |